The Board of Directors have inter alia approved the Audited Financial Results and Statements (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2024 and Final Dividend for the Financial Year 2023-24.

pdf

Rossari Biotech Ltd.

29 Apr 2024

699.35

-0.75%

Annual Report

Annual report for Rossari Biotech Ltd. for FY-2024

None

pdf

Rossari Biotech Ltd.

24 Apr 2024, 08:00PM

699.35

-0.75%

Company Update

Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Earnings Conference call for investors and analysts on Tuesday, April 30, 2024 at 04:00 PM IST.

pdf

Rossari Biotech Ltd.

20 Apr 2024

699.35

-0.75%

Board Meeting

Rossari Biotech Ltd - 543213 - Board Meeting Intimation for Audited Financial Statements And Financial Results …

BSE India

Rossari Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2024 ,inter alia, to consider and approve Audited Financial Statements and Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31st March, 2024 and recommend payment of Final Dividend for the Financial Year ended 31.03.2024.

pdf

Rossari Biotech Ltd.

12 Apr 2024

699.35

-0.75%

Corp. Note

Rossari Biotech Ltd - 543213 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyRossari Biotech Ltd 2CIN NO.L24100MH2009PLC194818 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 54.92 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Parul Gupta Designation: Company Secretary and Compliance Officer EmailId: investors@rossari.com Name of the Chief Financial Officer: Ketan Sablok Designation: Group Chief Financial Officer EmailId: ketan.sablok@rossari.com Date: 12/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Rossari Biotech Ltd.

06 Apr 2024

699.35

-0.75%

Corp. Note

Rossari Biotech Ltd - 543213 - Board Meeting Outcome for Outcome Of The Board Meeting Held …

BSE India

The Board of Directors have inter alia approved Incorporation of wholly owned subsidiary in Dubai, United Arab Emirates and Appointment of Mr. Sunil V as Chief Human Resource Officer and other matters.

pdf

VOTE: Is Rossari Biotech Ltd. worth buying?

66 Votes:

Buy 90.91%

Sell 3.03%

Hold 6.06%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf